Company Overview of Liquidia Technologies, Inc.
Liquidia Technologies, Inc., a nanotechnology company, designs, develops, and manufactures precisely engineered particles and films for various life and materials science applications. The company manufactures engineered particles using PRINT (Particle Replication In Non-Wetting Templates), a particle engineering and manufacturing technology. It applies its technology to develop products in pulmonary, ophthalmology, post-operative care, and vaccine areas, such as internal development of LIQ861 for inhaled and LIQ865 for pain relief, as well as a treatment for glaucoma. The company also licenses its PRINT particle technology and its cGMP manufacturing capabilities to support programs advanced...
419 Davis Drive
Morrisville, NC 27560
Founded in 2004
Key Executives for Liquidia Technologies, Inc.
Chief Executive Officer & Director
Co-Founder and Senior Scientist
Compensation as of Fiscal Year 2017.
Liquidia Technologies, Inc. Key Developments
Liquidia Technologies Announces Positive Phase 1 Data for LIQ865, Sustained-Delivery Print® Formulation of Bupivacaine for Post-Surgical Pain Relief
May 24 17
Liquidia Technologies, Inc. announced initial data from its LIQ865 internal clinical development program, which is a PRINT® formulation for the sustained-delivery of free base bupivacaine for post-surgical pain relief. The phase 1 trial, marking the first evaluation of LIQ865 in humans, was a randomized, controlled, double-blind study evaluating the safety, pharmacokinetic profile and pharmacodynamic response of a single-ascending dose in healthy adult males. Topline data indicate that LIQ865 doses were well tolerated and the pharmacodynamic response was consistent with a local anesthetic effect lasting for three or more days. Liquidia is developing LIQ865 with the goal of providing at least three days of post-surgical pain relief with a single administration, potentially minimizing or avoiding the need for opioid analgesics. There are over 80 million inpatient and outpatient surgeries performed every year, with the majority of surgeries requiring opioids to treat moderate to severe post-operative pain. A minority of these individuals will become long-term users and have the potential for opioid misuse and addiction. The phase 1 clinical trial results for LIQ865 further validate the remarkably broad applicability of the PRINT technology across virtually any therapeutic area. This phase 1 randomized, controlled, double-blind study evaluated the safety and pharmacokinetics/pharmacodynamics of single ascending doses of LIQ865 injection in 28 healthy adult male volunteers. This was a single site study conducted in Copenhagen, Denmark under a Clinical Trial Authorisation and Independent Ethics Committee approval. Each trial participant received active drug in the medial aspect of one calf and control in the other calf.
Liquidia Technologies To Reportedly Go Public
Jan 30 17
Liquidia Technologies, Inc., which is backed by the Bill & Melinda Gates Foundation Asset Trust may reportedly come up with an Initial Public Offering in Singapore in 2017 at a valuation of SGD 300 million.
Liquidia Technologies, Inc. Appoints Arthur S. Kirsch as Director and Chairman of the Audit Committee
Dec 13 16
Liquidia Technologies, Inc. announced the appointment of Arthur S. Kirsch to its board of directors and named him Chairman of the audit committee. Mr. Kirsch is currently a Senior Advisor with GCA Global, LLC, and brings to Liquidia over 30 years of experience in investment banking and equity capital markets, as well as extensive knowledge of the healthcare and life sciences industries.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|